Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualing Pharmaceutical-B, and others [3]. Core Insights - The pharmaceutical sector has outperformed the market, with a focus on the potential of innovative drugs and the CD73 target in cancer immunotherapy [4][5]. - The report highlights the promising clinical progress of CD73 inhibitors, with several products in various stages of clinical trials [21][25]. Summary by Sections Industry Investment Rating - The report provides a list of recommended companies with "Buy" and "Hold" ratings, indicating strong investment potential in the pharmaceutical sector [3]. Industry Performance - The pharmaceutical sector rose by 1.13%, outperforming the CSI 300 index by 0.25 percentage points, with innovative drugs and vaccines leading the performance [5][32]. Company Dynamics - Companies such as Lepu Medical and Sunshine Nuohua have made significant announcements regarding new product approvals and clinical trial progress, indicating a robust pipeline and growth potential [33][34]. Industry Trends - The report discusses the increasing focus on innovative drugs and the impact of regulatory changes on the pharmaceutical landscape, suggesting a shift towards high-efficiency business models in the industry [31][40].

Group 1: Sales and Revenue Projections - The projected revenue for the new pharmaceutical raw materials market in 2024 is 180 million, with expectations for 2025 being similarly optimistic [1] - The total sales revenue for the company in 2025 is estimated to be around 850 million, with a growth rate of approximately 10% expected due to new capacity being released [3] - The revenue from old products may see a slight decline in 2025, but overall income is expected to grow in 2026 after the expansion of Celecoxib [2] Group 2: Production Capacity and Utilization - The production capacity for Celecoxib is set to increase from 170 tons to 500-600 tons by the end of this year [1] - The utilization rate for the first phase of the second plant is expected to be around 60-70% in 2025, with one workshop having completed expansion in May [2] - Two workshops in the second phase of the second plant are expected to begin trial production in the second half of this year, with full capacity release anticipated in 2026 [2] Group 3: Market and Competitive Landscape - The company faces competition from Indian firms, with varying cost advantages across different products; however, the company excels in synthesis process maturity and R&D speed [3] - The company anticipates strong sales performance for new products such as Rivaroxaban, Apixaban, and others in the future [3] Group 4: Research and Development - The company plans to maintain a high level of R&D investment, projected to be over 7% of revenue in 2025 and beyond [2] - The new R&D building is expected to be operational this year, leading to an increase in personnel and corresponding R&D expenditure [2]

证券代码：300636 证券简称：同和药业 公告编号：2025-036 江西同和药业股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次回购注销的限制性股票数量共计1,575,855股，回购金额 合计为13,145,249.25元，回购股数占回购注销前公司总股本 421,527,350股的比例为0.3738%。本次回购注销完成后，公司总股本 由421,527,350股变更为419,951,495股。 2、本次被回购注销限制性股票的总人数为181人；其中因离职被 回购注销限制性股票的人数为5人，回购价格为7.71元/股；因公司层 面业绩未达到"以2021年的净利润为基数，2024年净利润增长率不低 于130%"的考核目标被回购注销限制性股票的人数为176人，首次授 予部分回购价格为8.35元/股，暂缓授予部分回购价格为8.08元/股。 3、本次部分限制性股票回购注销事宜已于2025年6月5日在中国 证券登记结算有限责任公司深圳分公司办理完成。 江西同和药业股份有限公司（以下简称"公司"）于202 ...

Group 1 - Guangdian Electric's wholly-owned subsidiary plans to sell 5.91% stake in Shanghai Winshun Electric Technology Co., Ltd. to Yapp Automotive Parts Co., Ltd. for 62.63 million yuan, aiming to optimize asset structure [1] - Anhui Natural Gas received approval for the registration of 500 million yuan short-term financing bonds and 600 million yuan medium-term notes, valid for two years [1] - Kirin Security received government subsidies totaling 6.48 million yuan, which are related to revenue [2] Group 2 - Junshi Biosciences received approval for two new indications for its self-developed drug, Oncorhynchus monoclonal antibody injection, targeting adult patients with heterozygous familial hypercholesterolemia and non-familial hypercholesterolemia [3] - China Resources Double Crane's subsidiary passed GMP compliance inspection for small and large volume injection production lines [4] - Nanjing Public Utilities' board approved the absorption and merger of its wholly-owned subsidiary, Nanjing Jinguang Industry Co., Ltd. [7] Group 3 - Boya Bio received drug registration certificate for human immunoglobulin (pH4) in the Dominican Republic, valid until August 12, 2029 [8] - Jizhi Co. announced that its controlling shareholder and actual controller committed not to reduce their shareholdings until December 31, 2025 [9] - Yuhua Tian won a bid for the integrated urban management project in Lanzhou City, with a total service subsidy of 353 million yuan [10] Group 4 - Anke Rui obtained five invention patent certificates related to various energy management and control technologies [11] - Kebo Da's wholly-owned subsidiary plans to acquire 100% of Czech IMI Company for approximately 9.43 million euros to enhance global production layout [13] - Yantian Port announced a cash dividend of 1.30 yuan per 10 shares, totaling 676 million yuan [14] Group 5 - Huawang Technology plans to distribute a cash dividend of 0.45 yuan per share and a capital reserve increase of 0.20 shares per share [15] - Kabe Yi established a wholly-owned subsidiary in Japan to enhance its business layout [16] - Dongcheng Pharmaceutical's subsidiary received approval for the marketing of sodium fluoride injection, a PET radiopharmaceutical [18] Group 6 - Huaxin New Materials' subsidiary received two utility model patent certificates for innovative devices [19] - Lingang Steel's new 2290 cubic meter blast furnace has been successfully put into operation [21] - Xinlitai received drug registration certificate for Sacubitril/Valsartan tablets, the first of its kind in China [23] Group 7 - Aike Co.'s subsidiary received project designation notices from multiple clients for electric drive platform components [25] - Tonghe Pharmaceutical received drug registration certificate for Apixaban in South Korea [26] - Junting Hotel signed a cooperation agreement with Choice Hotels for exclusive brand usage in mainland China [28] Group 8 - Guangdong Hongtu plans to establish a wholly-owned subsidiary in Zhengzhou to enhance market layout [30] - Yuheng Pharmaceutical signed a joint promotion agreement for Pemafibrate tablets with Xinghe Pharmaceutical [31] - Chongqing Steel terminated the absorption and merger of its wholly-owned subsidiary, citing strategic advantages of independent operation [33] Group 9 - Jihong Co. announced the listing of its H-shares on the Hong Kong Stock Exchange [34] - Deshi Co. announced plans for shareholders to reduce their holdings by up to 0.3% [36] - Xinhai Medical's subsidiary received medical device registration for a dialysis fluid filter [42]

生产商名称：江西同和药业股份有限公司 证券代码：300636 证券简称：同和药业 公告编号：2025-035 江西同和药业股份有限公司 关于公司获得韩国药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 江西同和药业股份有限公司（以下简称"公司"）于近日收到韩 国食品药品安全部（MFDS）颁发的甲苯磺酸艾多沙班药品注册证书， 相关信息如下： 特此公告。 1/ 1 生产商地址：江西省奉新高新技术产业园区 认证范围：甲苯磺酸艾多沙班原料药 证书编号：2025-A1-1217 签发日期：2025.05.21 甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性 房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。 公司甲苯磺酸艾多沙班产品获得韩国药品注册证书，标志着公司 甲苯磺酸艾多沙班原料药获得了韩国市场的准入资格，将对公司进一 步扩大国际市场业务起到积极作用。由于医药行业的特点，相关产品 在国际市场的销售情况易受到市场环境变化、汇率波动等因素影响， 敬请广大投资者谨慎决策，注意防范投资风险。 江西同和药业股份有限公司董事会 二〇二五 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-034 江西同和药业股份有限公司 关于增资参股公司暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、 交易概述 2025 年 4 月 23 日，江西同和药业股份有限公司（以下简称"公 司"或"同和药业"）召开第四届董事会第四次会议和第四届监事会 第四次会议，会议审议通过了《关于增资参股公司的议案》，同意公 司以自有资金 1100 万元增资杭州渤雅生物医药有限公司（以下简称 "杭州渤雅"）。具体内容详见公司于 2025 年 4 月 25 日披露在中国证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上的《关于增资参股公司暨关联交易 的公告》（公告编号：2025-026）。 二、 交易进展情况 杭州渤雅与协议各方正式签署了《增资协议》，并于近日完成了 工商变更登记手续，取得了杭州市萧山区市场监督管理局下发的《营 业执照》。 （一）增资协议的主要内容如下： 1、各方一致同意由甲方（指同和药业和另外两 ...

Group 1: Company Performance and Market Position - The company's stock price is influenced by multiple factors, primarily determined by market participants and long-term performance [1] - The company maintains a clear strategy and stable operations in the specialized chemical raw materials sector, leveraging R&D, global market presence, and strong manufacturing capabilities for sustainable growth [1] - In Q1 2025, the company's revenue decreased by 9.47% year-on-year, while net profit fell by 52.3%, indicating a significant drop in profit margins due to lower market prices for certain products [2] Group 2: Investment and Strategic Decisions - The investment in Hangzhou Boya Biopharmaceutical Co., Ltd. was based on its market prospects and the synergy with the company's future planning and development strategy [2] - Hangzhou Boya Biopharmaceutical Co., Ltd., established in 2023, focuses on the development and production of long-acting complex injectables, led by a team with extensive experience in formulation development [2] Group 3: Capacity and Revenue Insights - The first plant has a capacity of 800 million, and the second plant has a capacity of 500 million, with a utilization rate of 60%, indicating potential revenue of approximately 1.1 billion; however, the actual revenue for 2024 is projected at 759 million [2] - The company aims to enhance R&D and expand production and sales in the specialized chemical raw materials sector to achieve stable and long-term value returns for shareholders [2]

证券代码：300636 证券简称：同和药业 公告编号：2025-033 江西同和药业股份有限公司 1、股东大会召开的时间：2025 年 05 月 16 日 2、股东大会的召开地点：江西省奉新县江西奉新高新技术产业 园区公司会议室 3、是否符合有关法律法规和公司章程的规定： 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东大会无否决议案的情形。 2.本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 本次股东大会由公司董事会召集，董事长庞正伟先生主持。会议 采用现场投票和网络投票相结合的表决方式进行表决。会议的召集、 召开、表决程序符合《中华人民共和国公司法》、《中华人民共和国证 券法》等法律、法规及规范性文件和公司章程的规定。 （二）出席会议的股东、股东代表及其持有股份情况： 1、股东出席的总体情况： 通过现场和网络投票的股东 180 人，代表股份 161,362,452 股， 占公司有表决权股份总数的 38.2804％。 其中：通过现场投票的股东 15 人，代表 ...

上海市通力律师事务所 关于江西同和药业股份有限公司 2024 年年度股东大会的法律意见书 致: 江西同和药业股份有限公司 上海市通力律师事务所(以下简称"本所")接受江西同和药业股份有限公司(以下简称 "公司")的委托, 指派本所陈理民律师、卓海萍律师(以下简称"本所律师")根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规范性 文件(以下统称"法律法规")及《江西同和药业股份有限公司章程》(以下简称"公司章程") 的规定就公司 2024 年年度股东大会(以下简称"本次股东大会")相关事宜出具法律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了核 查、验证。在进行核查验证过程中, 公司已向本所保证, 公司提供予本所之文件中的所有 签署、盖章及印章都是真实的, 所有作为正本提交给本所的文件都是真实、准确、完整和有 效的, 且文件材料为副本或复印件的, 其与原件一致和相符。 在本法律意见书中, 本所仅对本次股东大会召集和召开的程序、出席本次股东大会人员 资格和召集人资格及表决程序、表决结果是否符合法律法规和公司章程的规定发表意见, 并不对本 ...

证券代码：300636 证券简称：同和药业 公告编号：2025-032 关于参加江西辖区上市公司 2025 年投资者 江西同和药业股份有限公司董事会 二〇二五年五月十五日 网上集体接待日活动的公告 1/ 1 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，江西同和药业股份有限公司 （以下简称"公司"）将参加由江西省上市公司协会举办的"2025年 江西辖区上市公司投资者网上集体接待日活动"，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路 演"网站（http://rs.p5w.net），或关注微信公众号：全景财经， 或下载全景路演APP，参与本次互动交流，活动时间为2025年5月21 日（周三） 15:30-17:00。届时将在线就公司2024年度业绩、公司 治理、发展战略、经营状况、融资计划、股权激励和可持续发展等 投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊 跃参与！ 江西同和药业股份有限公司 特此公告！ ...